

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

April 24, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Notice of Board Meeting

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, May 15, 2025, *inter-alia*, to

- a. Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2025; and
- b. Recommend final dividend, if any, for the financial year 2024-25.

In continuation to our letter dated March 25, 2025, pursuant to the Company's Insider Trading Code, the trading window for dealing in the equity shares of the Company shall continue to remain closed from April 1, 2025 till 48 hours after the declaration of audited financial results of the Company for the quarter and financial year ended March 31, 2025 and final dividend, if any, for the financial year 2024-25 to the stock exchanges.

This is for your information and records.

Yours sincerely,
For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary